Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TERN-101 in NASH
NCT04328077Phase 2Completed
- Sponsor
- Terns Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TERN-101 in Nonalcoholic steatohepatitis (NASH), sponsored by Terns Pharmaceuticals. Started Jun 2020; status: completed.
02
Drugs
TERN-101
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04328077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328077.